Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) dropped 0.8% during mid-day trading on Friday . The stock traded as low as $19.06 and last traded at $19.70, with a volume of 62,376 shares. The stock had previously closed at $19.85.

ATRA has been the subject of several recent analyst reports. Jefferies Group reiterated a “buy” rating and issued a $22.00 target price (down previously from $26.00) on shares of Atara Biotherapeutics in a research note on Monday, May 9th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 19th. Canaccord Genuity reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, June 7th. Citigroup Inc. upped their target price on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a research note on Friday, August 19th. Finally, JMP Securities reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $27.29.

The company’s market capitalization is $567.58 million. The firm’s 50-day moving average is $22.18 and its 200-day moving average is $19.64.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. Equities research analysts forecast that Atara Biotherapeutics Inc. will post ($2.78) EPS for the current year.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 7,200 shares of the firm’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $20.36, for a total transaction of $146,592.00. Following the completion of the transaction, the chief executive officer now owns 223,228 shares of the company’s stock, valued at $4,544,922.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Isaac E. Ciechanover sold 12,000 shares of the firm’s stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $20.53, for a total value of $246,360.00. Following the transaction, the chief executive officer now directly owns 223,228 shares of the company’s stock, valued at approximately $4,582,870.84. The disclosure for this sale can be found here.

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.